Stockreport

Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%

PLUS THERAPEUTICS, Inc.  (PSTV) 
PDF HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing preci [Read more]